Also noted on generics: 30 March 2012

Generics and biosimilars Initiative

Building trust in cost-effective treatments

Sign up
eng / esp

Also noted on generics: 30 March 2012

Generics/General | Posted 30/03/2012 0 Post your comment

Watson in talks to buy Actavis
US generics manufacturer Watson is rumoured to be making a bid for Icelandic generics company Actavis, according to Bloomberg, creating one of the world’s largest generics companies in the process. Watson is reportedly in private talks to pay around Euros 4.5 billion for Actavis, with a deal likely to be announced after Easter.

Source: Bloomberg

Law may change pre-emption for generics safety labelling
To date generics manufacturers have been exempt from having to change labels to reflect new safety concerns until after the brand-name drug maker changes their labelling. However, this could soon change if Senate Judiciary Committee Chairman Mr Patrick Leahy gets his way. The Senator plans to introduce legislation that would permit generics manufacturers to proactively improve warning information in labelling even before the brand-name drug maker does.

Senator Leahy said ‘The Mensing decision creates a troubling inconsistency in the law with respect to prescription drugs, … if a consumer takes the brand-name version of drug, she can sue the manufacturer for inadequate warnings. If the pharmacy happens to give her the generic version, she will not be compensated for her injuries.’

Senator Leahy intends to introduce the legislation as early as the end of March 2012.

Source: Patrick Leahy

Glenmark Generics receives three ANDA approvals
Glenmark Generics received FDA approval of its abbreviated new drug applications (ANDAs) for generic ciclopirox gel 0.77% and levonorgestrel and ethinyl estradiol tablets on 1 March 2012 and for imiquimod cream 5%, their generic version of Medicis Pharmaceutical’s Aldara, on 7 March 2012.

Glenmark’s levonorgestrel and ethinyl estradiol tablets, to be marketed under the branded generic name of Marlissa, are a generic version of Duramed Pharmaceutical’s Nordette tablets. Ciclopirox gel 0.77% is the generic version of Medicis Pharmaceutical’s Loprox gel.

According to IMS Health, the ciclopirox dermatitis treatment had sales for the 12-month period ending September 2011 of greater than US$10 million, while the levonorgestrel and ethinyl estradiol oral contraceptives had sales of approximately US$50.84 million; and the imiquimod cream wart treatment had 2011 sales of approximately US$244 million.

Source: Glenmark Generics